PCSK9 and hepatocellular carcinoma: Similarly, in hepatocellular carcinoma (HCC), PCSK9 palmitoylation at Cys600 by ZDHHC16 enhances PTEN degradation, activating AKT-S473 phosphorylation and conferring sorafenib resistance (19).